EPHX2 and metabolic syndrome: In a food-induced metabolic-syndrome rat model, chronic oral treatment with trans-4-[4-(3-adamantan-1-ylureido)-cyclohexyloxy]-benzoic acid (t-AUCB), a potent sEH inhibitor [20], alleviated the signs of metabolic syndrome, including lipid abnormalities and structural and functional changes in the liver [21].